You are here

Article Text

Article menu
Download PDFPDF
Republished review
Republished paper: Arterial stiffness in chronic kidney disease: causes and consequences
  1. Colin D Chue1,
  2. Jonathan N Townend1,
  3. Richard P Steeds1,
  4. Charles J Ferro2
  1. 1Department of Cardiology, Queen Elizabeth Hospital Birmingham and University of Birmingham, Birmingham, UK
  2. 2Department of Nephrology, Queen Elizabeth Hospital Birmingham and University of Birmingham, Birmingham, UK
  1. Correspondence to Dr Charles J Ferro, Renal Unit, Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham B15 2TH, UK; charles.ferro{at}uhb.nhs.uk

Abstract

Chronic kidney disease is associated with elevated cardiovascular risk, and heart failure and arrhythmias are the biggest causes of cardiovascular death in this population. Increased arterial stiffness is a hallmark of chronic kidney disease and is associated with adverse alterations in cardiac structure and function that may predispose to an increased risk of cardiovascular death. These changes are already apparent in early kidney disease, which is highly prevalent in the developed world. The mechanisms underlying increased arterial stiffness in chronic kidney disease are undoubtedly complex, but an understanding is paramount to enable the development of novel therapeutic strategies to prevent or reverse this pathophysiology and therefore reduce the cardiovascular disease burden in this high-risk cohort.

  • Arterial stiffness
  • chronic kidney disease
  • heart failure
  • diastolic dysfunction
  • left ventricular hypertrophy
  • renal disease

http://dx.doi.org/10.1136/pgmj.2009.184879rep

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • This is a reprint of a paper that first appeared in Heart, June 2010, volume 96, pages 817–823.

    • Funding Genzyme Corporation, 4620 Kingsgate, Cascade Way, Oxford Business Park South, Oxford OX4 2SU, UK.

    • Competing interests CJF has received lecture and advisory board fees from Genzyme. All authors are recipients of an unrestricted educational grant from Genzyme Corporation. No medical writers were involved in the preparation of this manuscript.

    • Provenance and peer review Not commissioned; externally peer reviewed.